An introduction from  29
our management
- Chairman’s Statement
laboratory for testing. gh a series of multichannel aware-
- Letter from the CEO
We are also developing a treatment  ness-raising  programs  to  improve 
01 for Fabry Disease, another lysoso- the quantity and quality of informa-
Chiesi at a Glance
mal storage disorder, wherein the  tion available to clinicians, patients, 
02 novel  product  seeks  to  provide  a  and families.
Positive Impacts  less frequently-dosed, and therefo- The Global Rare Diseases Business  ce
and Challenges n
a
- Products and Patients re more patient-friendly treatment,  Unit is also actively building colla- gl
- Processes a 
associated also with reduced immu- borative relationships with all sta- t 
- Global Value Chain a
- Corporate Citizenship nogenicity, thus enhancing patients’  keholders in the rare disease space,  si 
e
i
safety. Fabry Disease is characteri- including for example International  h
C
03
sed by specific neurological, cuta- Rare Disease Research Consortium 
Chiesi’s contribution 
to the UN Sustainable  neous, renal, cardiovascular, coch- IRDiRC, European Confederation of 
Development Goals
leo-vestibular  and  cerebrovascular  Pharmaceutical Enterprises (EUCO-
04 manifestations. PE) as well as patient organisations 
Annexes
Beyond our treatments, Chiesi sup- all around the world.
- Impact Report
- Data, Methodology  ports the rare diseases field throu-
   and GRI Content Index